scholarly journals Breast Cancer Diagnostic System Final Report CRADA No. TC02098.0

2017 ◽  
Author(s):  
A. M. Rubenchik ◽  
L. B. DaSilva
Keyword(s):  
Breast Cancer ◽  
Diagnostic System ◽  
Final Report ◽  
Cancer Diagnostic

scholarly journals Design and analysis of a robust breast cancer diagnostic system based on multimode MR images

2021 ◽  
Vol 18 (4) ◽  
pp. 3578-3597
Author(s):  
Hong Yu ◽  
◽  
Wenhuan Lu ◽  
Qilong Sun ◽  
Haiqiang Shi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diagnostic System ◽  
Mr Images ◽  
Cancer Diagnostic

Support Vector Machine Based Diagnostic System for Breast Cancer Using Swarm Intelligence

2011 ◽  
Vol 36 (4) ◽  
pp. 2505-2519 ◽  
Author(s):  
Hui-Ling Chen ◽  
Bo Yang ◽  
Gang Wang ◽  
Su-Jing Wang ◽  
Jie Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Support Vector Machine ◽  
Swarm Intelligence ◽  
Diagnostic System ◽  
Support Vector

Final report and long-term outcomes: Phase I trial of a HER2 intracellular plasmid-based vaccine in HER2+ advanced stage breast cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 2619-2619
Author(s):  
Mary L. Disis ◽  
Yushe Dang ◽  
Andrew L. Coveler ◽  
Doreen Higgins ◽  
Jennifer Childs ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Immune Responses ◽  
Optimal Dose ◽  
P Value ◽  
Final Report ◽  
Linear Regression Models ◽  
Her2 Breast Cancer ◽  
Kaplan Meier ◽  
Number Of Patients ◽  
Vaccine Site

2619 Background: Vaccination with the intracellular domain (ICD) of HER2 in pre-clinical models is both immunogenic and protective against the development of mammary tumors. This study (NCT00436254) was designed to examine the safety and optimal immunogenic dose of a DNA-based vaccine encoding the HER2 ICD in subjects with HER2+ breast cancer. Methods: Sixty-six patients with stage III or IV HER2 + breast cancer in remission or with stable bone only disease were enrolled into three vaccine arms: 1 (10mcg dose of plasmid), 2 (100mcg) and 3 (500mcg). Vaccines were administered i.d. monthly for three immunizations. Endpoints included safety and optimal dose. HER2 specific IFN-gamma immune responses were evaluated and DNA persistence at the vaccine site was assessed. Toxicity and clinical outcomes were followed for 10 years. Results: The majority of vaccine-related toxicity was grade 1 (89%) and grade 2 (11%) and was not significantly different between the three dose arms. All Arms developed HER2 ICD immunity after vaccination, however, patients in Arm 2 and Arm 3 had significantly better immune responses (of higher magnitude and at most time points) than patients in Arm 1 (p=0.003 and p<0.001, respectively) after adjusting for baseline factors. At 60 weeks, the number of patients who maintained the greatest fold-difference in HER2 ICD immune responses from their baseline was highest in Arm 2 (73%) when compared to Arm 1 (47%) and Arm 3 (45%). Associations between ICD responses and plasmid DNA persistence at the vaccine site were estimated via linear regression models. HER ICD immunity after the end of immunizations, relative to baseline, was significantly lower in patients with DNA persistence at week 16 compared to those without persistence (p=0.02). Patients at the highest dose demonstrated the greatest incidence of plasmid persistence (92%) as compared to 33% in Arm 1 and 10% in Arm 2. The median time of follow-up was 118.6 months (Arm 1), 99.7 months (Arm 2), and 73.5 months (Arm 3). The median OS and PFS has not been reached in any Arm and did not differ with respect to treatment arm (Log-rank p-value 0.36 for OS, and 0.63 for PFS). However, we observed a separation of Kaplan-Meier curves for OS from about 40 months and curves for PFS from about 30 months, and the separation maintained until the end of the study for Arm 2 versus Arm 1 and Arm 3. One patient in Arm 2 developed lymphocytic colitis 2.2 years from enrollment deemed possibly related to vaccination. Conclusions: An intermediate dose (100mcg) of vaccine was immunogenic and associated with persistence of immunity at 60 weeks. A randomized phase II trial of the HER2 ICD plasmid-based vaccine in the neoadjuvant setting is in development. Clinical trial information: NCT00436254.

Final report of Breast Cancer Care Registry at the Kenyatta National Hospital, Nairobi.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12552-e12552
Author(s):  
Nicholas Anthony Othieno-Abinya ◽  
Alice Musibi ◽  
Catherine Nyongesa ◽  
Benjamin Njihia ◽  
Andrew Gachii ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Disease ◽  
Ductal Carcinoma ◽  
Clinical Care ◽  
Significant Proportion ◽  
Relative Survival ◽  
Final Report ◽  
Early Disease ◽  
National Hospital ◽  
Kenyatta National Hospital

e12552 Background: Breast cancer is the commonest cancer among women in Kenya. We wanted to examine breast cancer seen at the Kenyatta National Hospital in relation to local factors that influence prognosis and quality of life, local variations in treatment and outcomes; describe the clinical care patterns, monitor the safety of the therapies provided to patients in a routine clinic setting. Methods: A prospective study of patients with breast cancer between 11.08.2011 and 11.09.2014 inclusive. Data included demographic details, diagnostic and staging procedures, stage, treatment and outcome. Estimates of relative survival used period approach. hi-square tests and analysis of variance (ANOVA) were utilised to make comparisons. Cross sectional data are presented in proportions, means and medians. Results: Four hundred patients were included, age range 20 to 83, median 49 years. Out 312, 65 (20.8%) were obese. Eight of 397 (2%) were smokers and 22(5.5%) took alcohol. Early disease was diagnosed in 269 out of 354 (76%) and metastatic disease in 85(24%). Breast lump presented in 388 out of 400 (97%), breast pain in 104 out of 388 (26.8%). Fifteen of 394 (3.8%) had second breast cancer, 4 (1%) had had ovarian cancer and 9 (2.3%) had had had other malignancy. History of breast cancer in first and second-degree relative was elicited in 41 out of 394 (10.4%). Ductal carcinoma NOS was commonest in 343 (88.2%), lobular carcinoma in 9(2.5%). Cases by T stage were T1 - 25(7.2%), T2 -130(37.4%), T3 - 96(27.6%), T4 - 87(25%). Of 322 cases, 187(58.1%) were ER positive and 175 (54.4%) PR positive. Her2 positive cases were 78 out of 322 (24.2%). Neo adjuvant and adjuvant chemotherapy mainly consisted of combinations of cyclophosphamide and doxorubicin [AC] +/- a taxane[AC→T] ( mainly by medical oncologists) or AC+ 5-FU [CAF] (mainly by clinical oncologists). Of 305 cases 272 (89.2%) completed adjuvant therapy, 8(2.6%) died during treatment. Median overall survival was 57.1 months (95% CI; 55.6 to 59.5 months). For metastatic disease, median PFS was worse for patients < 40 years. Conclusions: Pathology and biology mirrored global situation, over 75% of patients had non metastatic disease. A significant proportion of early disease patients did not complete treatment.

Sign in / Sign up

Export Citation Format

Share Document